Atypical antipsychotic medications: Pharmacological profiles and psychological implications

Professional Psychology: Research and Practice

Volumn 31, Issue 6, 2000, Pages 628-640

  Rivas Vazquez, Rafael A ^a   Rey, Gustavo J ^a   Blais, Mark A ^a   Rivas Vazquez, Ana A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0034338366     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.31.6.628     Document Type: Article

References (126)

1. Alphs, L. D., & Anand, R. (1999). Clozapine: The commitment to patient safety. Journal of Clinical Psychiatry, 60(Suppl. 12), 39-42.
2. Atkinson, J. M., Coia, D. A., Gilmour, W. H., & Harper, J. P. (1996). The impact of education groups for people with schizophrenia on social functioning and quality of life. British Journal of Psychiatry, 168, 199-204.
3. Ayd, F. J. (1995). Lexicon of psychiatry, neurology, and the neurosciences. Baltimore: Williams & Wilkins.
4. Baldessarini, R. J., & Tarazi, F. I. (1996). Brain dopamine receptors: A primer on their current status. Harvard Review of Psychiatry, 3, 301-325.
5. Beasley, C. M., Tran, P. V., & Tamura, R. N. (1996). Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
6. Beck, A. T., & Rector, N. A. (1998). Cognitive therapy for schizophrenic patients. The Harvard Mental Health Letter, 15(6), 4-6.
7. Bender, K. J. (1997). Treating psychosis in the new millennium. Psychiatric Times, 14(Suppl.), 1-4.
8. Bhatara, V. S., Sharma, J. N., Gupta, S., & Gupta, Y. K. (1997). Rauwolfia serpentina: The first herbal antipsychotic. American Journal of Psychiatry, 154, 894.
9. Bilder, R. J. (1997). Neurocognitive impairment in schizophrenia and how it affects treatment options. Canadian Journal of Psychiatry, 42, 255-264.
10. Bleich, A., Brown, S. L., Kahn, R., & Van Praag, H. M. (1988). The role of serotonin in schizophrenia. Schizophrenia Bulletin, 14, 297-315.
11. Bondolfi, G., Dufour, H., & Patris, M. (1998). Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. American Journal of Psychiatry, 155, 499-504.
12. Borison, R. L., Arvanitis, L. A., & Miller, B. G. (1996). A comparison of five fixed doses of Seroquel (ICI-204, 636) with haloperidol and placebo in patients with schizophrenia. Schizophrenia Research, 18, 132.
13. Bowes, M. P. (1998). Better treatments for psychosis. Psychiatric Times, 10(Suppl.), 1-4.
14. Breier, A., Schreiber, J. L., Dyer, J., & Pickar, D. (1991). National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Archives of General Psychiatry, 48, 239-246.
15. Buchanan, R. W., Holstein, C., & Breier, A. (1994). The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry, 36, 717-725.
16. Carpenter, W. T. (1996). The treatment of negative symptoms: Pharmacological and methodological issues. British Journal of Psychiatry, 168(Suppl. 29), 17-22.
17. Carpenter, W. T., Conley, R. R., Buchanan, R. W., Breier, A., & Tamminga, C. A. (1995). Patient response and resource management: Another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152, 827-832.
18. Carpenter, W. T., Heinrich, D. W., & Alphs, L. D. (1985). Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440-452.
19. Casey, D. E. (1998). Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. Journal of Clinical Psychiatry, 59(Suppl. 3), 31-37.
20. Cassens, G., Inglis, A. K., Appelbaum, P. S., & Gutheil, T. G. (1990). Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bulletin, 16, 477-499.
21. Chakos, M. H., Lieberman, J. A., Bilder, R. M., Borenstein, M., Lerner, G., Bogerts, B., Wu, H., Kinon, B., & Ashtari, M. (1994). Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151, 1430-1436.
22. Clinical trial evaluations and outcome measures in psychiatry. (1998). Journal of Clinical Psychiatry, 59(Suppl. 12), 3-9.
23. Cole, J. O., Goldberg, S. C., & Klerman, G. L. (1964). Phenothiazine treatment in acute schizophrenia. Archives of General Psychiatry, 10, 246-261.
24. Conley, R. R., Love, R. C., Kelly, D. L., & Bartko, J. J. (1999). Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. American Journal of Psychiatry, 156, 863-868.
25. Conley, R. R., Tamminga, C. A., & Bartko, J. J. (1998). Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. American Journal of Psychiatry, 155, 914-920.
26. Cook, J. A., Pickett, S. A., Razzano, L., Fitzgibbon, G., Jonikas, J. A., & Cohler, J. J. (1996). Rehabilitation services for persons with schizophrenia. Psychiatric Annals, 26, 97-104.
27. Coryell, W. (1998). The treatment of psychotic depression. Journal of Clinical Psychiatry, 59(Suppl. 1), 22-27.
28. Cuffel, B. J., Alford, J., Fischer, E. P., & Owen, R. R. (1996). Awareness of illness in schizophrenia and outpatient treatment adherence. Journal of Nervous and Mental Disorders, 184, 653-659.
29. Daniel, D. G., Targum, S., Zimbroff, D., Mack, R., Zborowski, J., Morris, D., Sebree, T., & Wallin, B. (1995, December). Efficacy, safety and dose response of three doses of sertindole and three doses of Haldol in schizophrenic patients. Paper presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology, New York.
30. Daniel, D. G., & Whitcomb, S. R. (1998). Treatment of the refractory schizophrenic patient. Journal of Clinical Psychiatry, 59(Suppl. 1). 13-19.
31. Davis, K. L., Kahn, R. S., & Ko, G. (1991). Dopamine in schizophrenia: A review and reconceptualization. American Journal of Psychiatry, 148, 1474-1486.
32. De Keyser, J. (1993). Subtypes and localization of dopamine receptors in human brain. Neurochemistry International, 22, 83-93.
33. Dodge, M. R., & Goldberg, T. E. (1999). Associations between cognitive impairment and tardive dyskinesia: Another perspective. Journal of Clinical Psychiatry, 60(Suppl. 13), 17-21.
34. Duckworth, K., Nair, V., Patel, J. K., & Goldfinger, S. M. (1997). Lost time, found hope and sorrow: The search for self, connection, and purpose during "awakenings" on the new antipsychotics. Harvard Review of Psychiatry, 5, 227-233.
35. Expert Consensus Guideline Series. (1999). Treatment of schizophrenia 1999. Journal of Clinical Psychiatry, 60(Suppl. 11), 3-80.
36. Fenton, W. S., & McGlashan, T. H. (1997). We can talk: Individual psychotherapy for schizophrenia. American Journal of Psychiatry. 154, 1493-1495.
37. Fichtner, C. G., Hanrahan, P., & Luchins, D. J. (1998). Pharmacoeconomic studies of the atypical antipsychotic: Review and perspective. Psychiatric Annals, 28, 381-396.
38. Fogel, B. S. (1996). Drug therapy in neuropsychiatry. In B. S. Fogel & R. B. Schiffer (Eds.), Neuropsychiatry (pp. 223-256). Baltimore: Williams & Wilkins.
39. Glazer, W. M. (1999). Does loxapine have "atypical" properties? Clinical evidence. Journal of Clinical Psychiatry, 60(Suppl. 10), 42-46.
40. Glazer, W. M., & Dickson, R. A. (1998). Clozapine reduces violence and persistent aggression in schizophrenia. Journal of Clinical Psychiatry, 59(Suppl. 3), 8-14.
41. Glazer, W. M., & Johnstone, B. M. (1997). Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. Journal of Clinical Psychiatry, 57(Suppl. 10), 50-54.
42. Goldberg, T. E., & Weinberger, D. R. (1994). The effects of clozapine on neurocognition: An overview. Journal of Clinical Psychiatry, 55(Suppl. B), 88-90.
43. Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry, 153, 321-330.
44. Green, M. F., Marshall, B. D., Wirshing, W. C., Ames, D., Marder, S. R., McGurk, S., Kern, R. S., & Mintz, J. (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia. American Journal of Psychiatry, 154, 799-804.
45. Harvey, P. D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R. C., Hoblyn, J., & Davis, K. (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. American Journal of Psychiatry, 155, 1080-1086.
46. Harvey, P. D., & Keefe, R. S. (1997). Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectrums, 2(8), 41-55.
47. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
48. Hegarty, J. D., Baldessarini, R. J., & Tonen, M. (1994). One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry, 151, 1409-1416.
49. Herz, M. I. (1996). Psychosocial treatment. Psychiatric Annals, 26, 531-535.
50. Herz, M. I., & Lamberti, J. S. (1995). Prodromal symptoms and relapse prevention in schizophrenia. Schizophrenia Bulletin, 21, 541-551.
51. Hippius, H. (1999). A historical perspective of clozapine. Journal of Clinical Psychiatry, 60(Suppl. 12), 22-23.
52. Hogarty, G. E., Greenwald, D., Ulrich, R. F., Kornblith, S. J., DiBarry, A. L., Cooley, S., Carter, M., & Flesher, S. (1997). Three-year trials of personal therapy among schizophrenic patients living with or independent of family: II. Effects on adjustment of patients. American Journal of Psychiatry, 154, 1514-1524.
53. Hogarty, G. E., Kornblith, S. J., Greenwald, D., DiBarry, A. L., Cooley, S., Ulrich, R. F., Carter, M., & Flesher, S. (1997). Three-year trials of personal therapy among schizophrenic patients living with or independent of family: I. Description of study and effects on relapse rates. American Journal of Psychiatry, 154, 1504-1513.
54. Hughes, D. H. (1998). Pharmacologic management of the chronically aggressive psychiatric patient. Psychiatric Annals, 28, 367-370.
55. Jeste, D. V., Caligiuri, M. P., & Paulsen, J. S. (1995). Risk of tardive dyskinesia in older patients. Archives of General Psychiatry, 52, 756-765.
56. Jeste, D. V., Lohr, J. B., & Manley, M. (1992). Study of neuropathologic changes in the striatum following 4, 8, and 12 months of treatment with fluphenazine in rats. Psychopharmacology, 106, 154-160.
57. Jibson, M. D., & Tandon, R. (1996). A summary of research findings on the new antipsychotic drugs. The Psychiatry Forum, 16(5), 1-7.
58. Jibson, M. D., & Tandon, R. (1998). New atypical antipsychotic medications. Journal of Psychiatric Research, 32, 215-228.
59. Jones, H., Curtis, V. A., Wright, P., & Lucey, J. V. (1998). Neuroendocrine evidence that clozapine's serotonergic antagonism is relevant to its efficacy in treating hallucinations and other positive schizophrenic symptoms. American Journal of Psychiatry, 155, 838-840.
60. Kane, J. M. (1992). Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview. British Journal of Psychiatry, 160(Suppl. 17), 41-45.
61. Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
62. Kaplan, H. I., & Sadock, B. J. (1988). Synopsis of psychiatry (5th ed.). Baltimore: Williams & Wilkins.
63. Kapur, S., & Remington, G. (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
64. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. American Journal of Psychiatry, 155, 921-928.
65. Kee, K. S., Kern, R. S., Marshall, B. D., & Green, M. F. (1998, May). Risperidone versus haloperidol for perception of emotion in treatmentresistant schizophrenia: Preliminary findings. Paper presented at the 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada.
66. Kinon, B. J., & Lieberman, J. A. (1996). Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology, 124, 2-34.
67. Kopelowicz, A., & Liberman, R. P. (1998). Psychosocial treatments for schizophrenia. In P. Nathan & J. Gorman (Eds.), A guide to treatments that work (pp. 190-211). New York: Oxford University Press.
68. Kopelowicz, A., Liberman, R. P., Mintz, J., & Zarate, R. (1997). Comparison of efficacy of social skills training for deficit and nondeficit negative symptoms in schizophrenia. American Journal of Psychiatry, 154, 424-425.
69. Lee, M., Thompson, P., & Meltzer, H. Y. (1994). Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry, 55(Suppl. B), 82-87.
70. Liberman, R. P., Wallace, C. J., Blakwell, G., Kopelowicz, A., Vaccaro, J. V., & Mintz, J. (1998). Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. American Journal of Psychiatry, 155, 1087-1091.
71. Lieberman, J. A. (1996a). Atypical antipsychotic drugs as first-line treatment of schizophrenia: A rationale and hypothesis. Journal of Clinical Psychiatry, 57(Suppl. 11), 68-71.
72. Lieberman, J. A. (1996b). New developments in antipsychotic drug treatment. Psychiatric Times, 13(3), 41-43.
73. Lindenmayer, J. P., Iskander, A., Park, M., Apergi, F. S., Czobor, P., Smith, R., & Allen, D. (1998). Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study. Journal of Clinical Psychiatry, 59, 521-527.
74. Littrell, K. H. (1996). Reintegration studies: Maximizing outcomes. Journal of Clinical Psychiatry, 57, 320-321.
75. Littrell, K. H., & Littrell, S. H. (1998). Issues of reintegration and rehabilitation in schizophrenia. Psychiatric Annals, 28, 371-377.
76. Marder, S. R. (1998). Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry, 59(Suppl. 3), 21-25.
77. Marder, S. R., Davis, J. M., & Chouinard, G. (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: Combined results of the North American trials. Journal of Clinical Psychiatry, 58, 538-546.
78. Marder, S. R., & Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
79. Marder, S. R., & Van Putten, T. (1995). Antipsychotic medications. In A. F. Schatzberg & C. Nemeroff (Eds.), Textbook of psychopharmacology (pp. 247-261). Washington, DC: American Psychiatric Press.
80. Martin, J., Gomez, J. C., Garcia-Bernardo, E., Cuesta, M., Alvarez, E., & Gurpegui, M. (1997). Olanzapine in treatment-refractory schizophrenia: Results of an open-label study. Journal of Clinical Psychiatry, 58, 479-483.
81. Mavangell, L. B., Yudofsky, S. C., & Silver, J. M. (1999). Psychopharmacology and electroconvulsive therapy. In R. E. Hales, S. C. Yudofsky, & J. A. Talbott (Eds.), The American Psychiatric Press textbook of psychiatry (3rd ed., pp. 1025-1132). Washington, DC: American Psychiatric Press.
82. McGurk, S. R. (1999). The effects of clozapine on cognitive functioning in schizophrenia. Journal of Clinical Psychiatry, 60(Suppl. 12), 24-29.
83. McGurk, S. R., Green, M. F., Wirshing, W. C., Ames, D., Marshall, B. D., Marder, S. R., & Mintz, J. (1997). The effects of risperidone versus haloperidol on cognitive functioning in treatment-resistant schizophrenia: The Trail Making Test. CNS Spectrums, 2(8), 60-64.
84. McGurk, S. R., & Meltzer, H. Y. (1998, May). The effects of atypical antipsychotics on cognitive functioning in schizophrenia. Paper presented at the 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada.
85. Meltzer, H. Y. (1989). Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypotheses of schizophrenia. Psychopharmacology, 99(Suppl. 1), 18-27.
86. Meltzer, H. Y. (1992). Dimensions of outcome with clozapine. British Journal of Psychiatry, 160, 46-53.
87. Meltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
88. Meltzer, H. Y., & Jayathilake, K. (1999). Low-dose loxapine in the treatment of schizophrenia: Is it more effective and more "atypical" than standard-dose loxapine? Journal of Clinical Psychiatry, 60(Suppl. 10), 47-51.
89. Menditto, A. A., Beck, N. C., Stuve, P., Fisher, J. A., Stacy, M., Logue, M. B., & Baldwin, L. J. (1996). Effectiveness of clozapine and a social learning program for severely disabled psychiatric inpatients. Psychiatric Services, 47, 46-51.
90. Miller, C. H., Mohr, F., Umbricht, D., Woerner, M., Fleischhacker, W. W., & Lieberman, J. A. (1998). The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. Journal of Clinical Psychiatry, 59, 69-75.
91. Moriarty, P. J., Lieber, D., Serper, M. R., & Harvey, P. D. (1998, May). Improvement in information processing performance with novel antipsychotic treatment. Paper presented at the 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada.
92. Murphy, D. L., Andrews, A. M., Wichems, C. H., Li, Q., Tohda, M., & Greenberg, B. (1998). Brain serotonin neurotransmission: An overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Journal of Clinical Psychiatry, 58(Suppl. 15), 4-12.
93. 2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry, 156, 869-875.
94. Owens, M. J., & Risch, S. C. (1995). Atypical antipsychotics. In A. F. Schatzberg & C. Nemeroff (Eds.), Textbook of psychopharmacology (pp. 263-280). Washington, DC: American Psychiatric Press.
95. Perkins, D. O., & Lieberman, J. A. (1998). Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. American Journal of Psychiatry, 155, 272-276.
96. Perlick, D., Stastny, P., Mattis, S., & Teresi, J. (1992). Contribution of family, cognitive, and clinical dimensions to long-term outcome in schizophrenia. Schizophrenia Research, 6, 257-265.
97. Peuskens, J. (1999). The evolving definition of treatment resistance. Journal of Clinical Psychiatry, 60(Suppl. 12), 4-8.
98. Physicians' desk reference (53rd ed.). (1999). Montvale, NJ: Medical Economics Data.
99. Pies, R. (1997). The four horsemen of the atypicals. Psychiatric Times, 14(3), 18-21.
100. Pies, R. (1998a). The horsemen are joined: The newer atypical antipsychotics. Psychiatric Times, 15(1), 22-27.
101. Pies, R. (1998b). Progress in psychoses: Safety and efficacy of atypical antipsychotics in schizophrenic and demented patients. Psychiatric Times, 15(5), 28-30.
102. Pinto, A., La Pia, S., Mennella, R., Giorgio, D., & DeSimone, L. (1999). Cognitive-behavioral therapy and clozapine for clients with treatment-refractory schizophrenia. Psychiatric Services, 50, 901-904.
103. 2A receptor effects of antipsychotics: Bridging basic and clinical findings using PET. Journal of Clinical Psychiatry, 60(Suppl. 10), 15-19.
104. Richelson, E. (1999). Receptor pharmacology of neuroleptics: Relation to clinical effects. Journal of Clinical Psychiatry, 60(Suppl. 10), 5-14.
105. Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., & Charney, D. (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New England Journal of Medicine, 337, 809-815.
106. Safferman, A., Lieberman, J. A., Kane, J. M., Szymanski, S., & Kinon, B. (1991). Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247-261.
107. Serper, M. R., & Chou, J. Y. C. (1997). Novel neuroleptics improve attentional functioning in schizophrenic patients: Ziprasidone and aripiprazole. CNS Spectrums, 2(8), 56-59.
108. Shepherd, G. (1988). Neurobiology (2nd ed.). New York: Oxford University Press.
109. Small, J., Hirsch, S., & Arvanitis, L. (1997). Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Archives of General Psychiatry, 54, 549-557.
110. Spohn, H. E., & Strauss, M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. Journal of Abnormal Psychology, 98, 478-486.
111. Stahl, S. M. (1998). Psychopharmacology of antipsychotics. London: Martin Dunitz.
112. Stahl, S. M. (1999). What makes an antipsychotic atypical? Journal of Clinical Psychiatry, 59(Suppl. 8), 403-404.
113. Strauss, M. E., Reynolds, K. S., Jayaram, G., & Tune, L. E. (1990). Effects of anticholinergic medication on memory in schizophrenia. Schizophrenia Research, 3, 127-129.
114. Tandon, R., Milner, K., & Jibson, M. D. (1999). Antipsychotics from theory to practice: Integrating clinical and basic data. Journal of Clinical Psychiatry, 60(Suppl. 8), 21-28.
115. Tohen, M., & Zarate, C. A. (1998). Antipsychotic agents and bipolar disorder. Journal of Clinical Psychiatry, 59(Suppl. 1), 38-48.
116. Tollefson, G. D., Beasley, C. M., Tran, P. V., Street, J. S., Krueger, J. A., Tamura, R. N., Graffeo, K. A., & Thieme, M. E. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
117. Tollefson, G. D., & Sanger, T. M. (1997). Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry, 154, 466-474.
118. Tollefson, G. D., Sanger, T. M., Lu, Y., & Thieme, M. E. (1998). Depressive signs and symptoms in schizophrenia. Archives of General Psychiatry, 55, 250-258.
119. Tran, P. V., Dellva, M. A., Tollefson, G. D., Beasley, C. M., Potvin, J. H., & Kiesler, G. M. (1997). Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry, 58, 205-211.
120. Umbricht, D., & Kane, J. M. (1995). Risperidone: Efficacy and safety. Schizophrenia Bulletin, 21, 593-606.
121. Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999). Evidence of clozapine effectiveness in schizophrenia: A systematic review and metaanalysis of randomized trials. American Journal of Psychiatry, 156, 990-999.
122. Wyatt, R. J. (1998). Cost effectiveness of the new versus older antipsychotic medications. Journal of Clinical Psychiatry, 59, 322-328.
123. Wyatt, R. J., Green, M. F., & Tuma, A. H. (1997). Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: A re-analysis of the Camarillo State Hospital data. Psychological Medicine, 27, 261-268.
124. Zayas, E., & Grossberg, G. T. (1998). The treatment of psychosis in late life. Journal of Clinical Psychiatry, 59(Suppl. 1), 5-10.
125. Zeneca Pharmaceuticals. (1997). Seroquel tablets (quetiapine fumarate): A new atypical antipsychotic. Wilmington, DE: Author.
126. Zimbroff, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., Sebree, T. B., Wallin, B. A., & Kashkin, K. B. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154, 782-791.